<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20230912180730&amp;utm_content =1vU ePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;fc =20230708114047<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20230912180730&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 12 日，星期二 22:07:31 +0000</lastbuilddate><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> SPHK2/S1P 轴改变平滑肌细胞组蛋白乙酰基可促进肺动脉高压</title><link/>https://pubmed.ncbi.nlm.nih.gov/37698017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>结论：人肺动脉平滑肌细胞中 SPHK2 的表达及其对可逆组蛋白 H3K9 乙酰化的激活代表了可以减轻 PH 血管重塑的新治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 12 日。doi：10.1161/CIRCRESAHA.123.322740。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：对肺动脉高压 (PH) 血管重塑的表观遗传调控知之甚少。转录调节、组蛋白乙酰化密码改变染色质可及性以促进转录激活。我们的目标是确定破坏 PH 中表观遗传平衡的上游机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：人肺动脉平滑肌细胞 (PASMC)、人特发性肺动脉高压 (iPAH)：人 PASMC、iPAH 肺组织、衰竭供体肺组织、人肺微血管内皮细胞、iPAH:PASMC 和非 iPAH:PASMC RNA-利用 seq 数据库、NanoString nCounter 以及使用核酸酶进行靶标切割和释放来研究组蛋白乙酰化、超乙酰化靶标、蛋白质和基因表达、鞘脂激活、细胞增殖和基因靶标识别。SPHK2（鞘氨醇激酶 2）敲除与缺氧 3 周后对照 C57BL/6NJ 小鼠并评估 PH 指数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现人类 PASMC 易受转录促进表观遗传介质组蛋白乙酰化的影响，导致转录机制发生改变，并证实其在 PH:PASMC 细胞中的病理存在。我们报告 SPHK2 在 iPAH 肺中升高高达 20 倍在 PH 发病过程中，核 SPHK2 激活核生物活性脂质 S1P（1-磷酸鞘氨醇）催化酶，并通过 EMAP 介导转录调节组蛋白 H3K9 乙酰化（乙酰组蛋白 H3 赖氨酸 9 [Ac-H3K9]） （内皮单核细胞激活多肽） II. 在 iPAH 肺中，我们发现可逆表观遗传转录调节剂 Ac-H3K9:H3 的比例升高了 4 倍。SPHK2 的缺失抑制了小鼠缺氧诱导的 PH 和 Ac-H3K9。我们发现肺血管内皮细胞是 EMAP II/SPHK2/S1P 轴的启动因子，通过组蛋白 H3K9 的高度乙酰化，改变具有 PASMC 特异性的乙酰组。利用靶标下的切割并使用核酸酶释放，我们进一步表明 EMAP II 介导的SPHK2 有潜力通过超乙酰化 KLF4 顺式调节元件来修改多能性因子 KLF4（Krüppel 样因子 4）的局部转录机制，而 SPHK2 的删除和靶向抑制则可以挽救改变转录的 Ac-H3K9。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：人肺动脉平滑肌细胞中 SPHK2 的表达及其对可逆组蛋白 H3K9 乙酰化的激活代表了可以减轻 PH 血管重塑的新治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37698017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37698017</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322740>10.1161/CIRCRESAHA.123.322740</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37698017</guid><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><dc:creator> A 杜沙尼 CU 拉纳辛哈</dc:creator><dc:creator>玛吉·霍洛汉</dc:creator><dc:creator>卡林·博格</dc:creator><dc:creator>黛博拉·多纳休</dc:creator><dc:creator>拉斐尔·D·库克</dc:creator><dc:creator>马丁·格里格</dc:creator><dc:creator>安德鲁·金</dc:creator><dc:creator>维多利亚·普罗普利斯</dc:creator><dc:creator>弗朗西斯·卡斯特利诺</dc:creator><dc:creator>玛格丽特·施瓦茨</dc:creator><dc:date>2023-09-12</dc:date><dc:source>流通研究</dc:source><dc:title>SPHK2/S1P 轴改变平滑肌细胞组蛋白乙酰基可促进肺动脉高压</dc:title><dc:identifier>下午：37698017</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322740</dc:identifier></item><item><title>实施预防科学以消除医疗保健不平等，实现心血管健康：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37698007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>预防心血管及相关疾病是实现理想心血管健康以改善个人和社区整体健康和福祉的基础。健康的社会决定因素和医疗保健不平等会对理想的心血管健康和疾病预防产生不利影响。有效和公平的方式需要协调的多学科和多层次的方法。在这份科学声明中，我们研究...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 12 日。doi：10.1161/CIR.0000000000001171。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">预防心血管及相关疾病是实现理想心血管健康以改善个人和社区整体健康和福祉的基础。健康的社会决定因素和医疗保健不平等会对理想的心血管健康和疾病预防产生不利影响。有效和公平的方式需要协调的多学科和多层次方法。在这份科学声明中，我们在利用现有资源减少医疗保健不平等并优化预防性心血管护理服务的背景下，研究了实现理想心血管健康及其相关状况的障碍我们主要讨论（1）涉及直接患者护理的跨医疗保健环境的干预措施，（2）利用医疗保健技术，（3）优化多专业/多专业合作和干预措施，（4）吸引当地社区，以及（5）改善社区。通过与健康相关的政府政策来改善环境，所有这些政策的重点都是使所有人都享有公平的理想心血管健康。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37698007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37698007</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001171>10.1161/CIR.0000000000001171</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37698007</guid><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><dc:creator>阿南迪塔·阿加瓦拉</dc:creator><dc:creator>贾迪普·帕特尔</dc:creator><dc:creator>詹娜·斯蒂芬斯</dc:creator><dc:creator>沙马里尔·罗伯森</dc:creator><dc:creator>朱厄尔·斯科特</dc:creator><dc:creator>特里萨·贝基</dc:creator><dc:creator>伊丽莎白·杰克逊</dc:creator><dc:creator>美国心脏协会预防科学委员会、流行病学和预防委员会、心血管和中风护理委员会、临床心脏病学委员会、生活方式和心脏代谢健康委员会、周围血管疾病委员会、护理质量和结果研究委员会以及中风理事会</dc:creator><dc:date>2023-09-12</dc:date><dc:source>循环</dc:source><dc:title>实施预防科学以消除医疗保健不平等，实现心血管健康：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37698007</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001171</dc:identifier></item><item><title>导管消融可改善 AF 和终末期 HF 患者的预后</title><link/>https://pubmed.ncbi.nlm.nih.gov/37697073/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 11 日。doi：10.1038/s41569-023-00932-9。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37697073/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37697073</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00932-9>10.1038/s41569-023-00932-9</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37697073</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>卡琳娜·黄</dc:creator><dc:date>2023-09-11</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>导管消融可改善 AF 和终末期 HF 患者的预后</dc:title><dc:identifier>下午:37697073</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00932-9</dc:identifier></item><item><title>梗死重塑中的心脏周细胞多样性：不仅仅是血管支持细胞？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37695834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):899-902. doi: 10.1161/CIRCULATIONAHA.123.065676. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37695834</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065676>10.1161/CIRCULATIONAHA.123.065676</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695834</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>托马斯·摩尔-莫里斯</dc:creator><dc:creator>西尔维娅·M·埃文斯</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>梗死重塑中的心脏周细胞多样性：不仅仅是血管支持细胞？</dc:title><dc:identifier>下午:37695834</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065676</dc:identifier></item><item><title> Cosentino 和 Marino 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环刺突蛋白”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):906-907. doi: 10.1161/CIRCULATIONAHA.123.064000. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37695833</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064000>10.1161 / CIRCULATIONAHA.123.064000</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695833</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>马可·科森蒂诺</dc:creator><dc:creator>弗兰卡·马里诺</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Cosentino 和 Marino 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环刺突蛋白”的信函</dc:title><dc:identifier>下午:37695833</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064000</dc:identifier></item><item><title>血管内成像引导下经皮冠状动脉介入治疗对慢性完全闭塞的预后影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):903-905. doi: 10.1161/CIRCULATIONAHA.123.065876. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37695832</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065876>10.1161 / CIRCULATIONAHA.123.065876</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695832</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>洪大卫</dc:creator><dc:creator>金尚民</dc:creator><dc:creator>李相耀</dc:creator><dc:creator>崔基弘</dc:creator><dc:creator>宋永斌</dc:creator><dc:creator>李正英</dc:creator><dc:creator>李承宰</dc:creator><dc:creator>尹京浩</dc:creator><dc:creator>赵在英</dc:creator><dc:creator>金灿俊</dc:creator><dc:creator>安孝石</dc:creator><dc:creator>南昌旭</dc:creator><dc:creator>尹赫俊</dc:creator><dc:creator>朴容焕</dc:creator><dc:creator>王秀利</dc:creator><dc:creator>郑振玉</dc:creator><dc:creator>宋必尚</dc:creator><dc:creator>都俊亨</dc:creator><dc:creator>赵尚浩</dc:creator><dc:creator>尹昌焕</dc:creator><dc:creator>姜敏圭</dc:creator><dc:creator>许真仙</dc:creator><dc:creator>李宽勇</dc:creator><dc:creator>林英孝</dc:creator><dc:creator>赵润亨</dc:creator><dc:creator>赵镇万</dc:creator><dc:creator>张宇振</dc:creator><dc:creator>千国镇</dc:creator><dc:creator>朴泽圭</dc:creator><dc:creator>杨正勋</dc:creator><dc:creator>崔胜赫</dc:creator><dc:creator>权贤哲</dc:creator><dc:creator>韩柱容</dc:creator><dc:creator>李柱明</dc:creator><dc:creator>翻新综合体 PCI 调查员</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>血管内成像引导下经皮冠状动脉介入治疗对慢性完全闭塞的预后影响</dc:title><dc:identifier>下午:37695832</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065876</dc:identifier></item><item><title>为什么预防心脏病学的新疗法可能面临马拉松而不是短跑</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):859-861. doi: 10.1161/CIRCULATIONAHA.122.063099. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37695831</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063099>10.1161/CIRCULATIONAHA.122.063099</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695831</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>乔安娜·卡瓦利尔</dc:creator><dc:creator>尼尚·P·沙阿</dc:creator><dc:creator>迈克尔·A·炽热</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>为什么预防心脏病学的新疗法可能面临马拉松而不是短跑</dc:title><dc:identifier>下午:37695831</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.063099</dc:identifier></item><item><title> Schwartz 和 Prasad 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):908-909. doi: 10.1161/CIRCULATIONAHA.123.064414. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37695830</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064414>10.1161/CIRCULATIONAHA.123.064414</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695830</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·大卫·施瓦茨</dc:creator><dc:creator>卡姆拉·K·普拉萨德</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Schwartz 和 Prasad 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信函</dc:title><dc:identifier>下午:37695830</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064414</dc:identifier></item><item><title> Yonker 等人对有关文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信件的回应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):910-911. doi: 10.1161/CIRCULATIONAHA.123.065629. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37695829</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065629>10.1161/CIRCULATIONAHA.123.065629</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695829</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>莱尔·M·扬克</dc:creator><dc:creator>阿莱西奥·法萨诺</dc:creator><dc:creator>大卫·R·沃尔特</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Yonker 等人对有关文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信件的回应</dc:title><dc:identifier>下午:37695829</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065629</dc:identifier></item><item><title>通过血脑屏障的荷尔蒙把关控制着蚂蚁的种姓特定行为</title><link/>https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>在这里，我们揭示了血脑屏障 (BBB) 在调节蚂蚁复杂的社会行为中发挥的意想不到的作用。利用 scRNA-seq，我们发现了一种称为保幼激素酯酶 (Jhe) 的关键激素降解酶位于 BBB 中。 ），我们表明这种定位控制着进入大脑的保幼激素（JH3）的水平。Jhe水平的操纵会重新编程蚂蚁种姓之间的大脑转录组。虽然蚂蚁Jhe被保留并在BBB内的细胞内发挥作用，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 24 日：S0092-8674(23)00856-5. doi: 10.1016/j.cell.2023.08.002. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在这里，我们揭示了血脑屏障 (BBB) 在调节蚂蚁复杂的社会行为中发挥的意想不到的作用。利用 scRNA-seq，我们发现了一种称为保幼激素酯酶 (Jhe) 的关键激素降解酶位于 BBB 中。 ），我们表明这种定位控制着进入大脑的保幼激素（JH3）的水平。Jhe 水平的操纵会重新编程蚂蚁种姓之间的大脑转录组。尽管蚂蚁 Jhe 被保留并在 BBB 内发挥细胞内功能，但我们发现果蝇Jhe 天然存在于细胞外。蚂蚁 Jhe 在果蝇 BBB 中的异源表达改变了苍蝇的行为，以模仿蚂蚁中所看到的行为。最引人注目的是，操纵蚂蚁中的 Jhe 水平重新编程了工蚁种姓之间的复杂行为。因此，我们的研究揭示了一种非凡的、潜在的BBB 作为调节社会行为的神经激素途径的分子守门人的保守作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37683635</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.002>10.1016/j.cell.2023.08.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37683635</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>鞠林洋</dc:creator><dc:creator>卡尔·M·格拉斯塔德</dc:creator><dc:creator>盛立红</dc:creator><dc:creator>扬科·戈斯波西奇</dc:creator><dc:creator>卡勒姆·J·金威尔</dc:creator><dc:creator>肖恩·M·戴维森</dc:creator><dc:creator>莎拉·D·科赫</dc:creator><dc:creator>罗伯托·博纳西奥</dc:creator><dc:creator>雪莱·伯杰</dc:creator><dc:date>2023-09-08</dc:date><dc:source>细胞</dc:source><dc:title>通过血脑屏障的荷尔蒙把关控制着蚂蚁的种姓特定行为</dc:title><dc:identifier>下午:37683635</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.002</dc:identifier></item><item><title> Patescibacteria 的基因操作为微生物暗物质和表生生活方式提供了机制见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description> Patescibacteria，也称为候选辐射门 (CPR)，是一组多样化的细菌，构成了微生物暗物质中不成比例的大部分。它的少数培养成员主要属于糖杆菌，在宿主放线菌上作为表生菌生长。由于缺乏合适的工具，这种生活方式的遗传基础和 Patescibacteira 的其他独特特征仍未得到探索。在这里，我们表明糖细菌表现出天然的能力，并且我们利用... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 30 日：S0092-8674(23)00906-6. doi: 10.1016/j.cell.2023.08.017. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Patescibacteria，也称为候选辐射门 (CPR)，是一组多样化的细菌，构成了微生物暗物质中不成比例的大部分。它的少数培养成员主要属于糖杆菌，在宿主放线菌上作为表生菌生长。由于缺乏合适的工具，这种生活方式的遗传基础和 Patescibacteira 的其他独特特征仍未被探索。在这里，我们表明糖杆菌表现出天然的能力，并且我们利用这种特性进行基因操作。荧光蛋白标记的糖杆菌的成像提供了高时空解决伴随表生生长的现象，转座子插入测序（Tn-seq）全基因组筛选揭示了神秘的糖细菌基因对其宿主生长的贡献。最后，我们利用宏基因组数据提供基于蛋白质结构的尖端技术支持 Southlakia epibion​​ticum 菌株及其相应宿主以色列放线菌作为解锁表生生活方式分子基础的模型系统的生物信息资源。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37683634</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.017>10.1016/j.cell.2023.08.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37683634</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>王亚熙</dc:creator><dc:creator>拉里·加拉格尔</dc:creator><dc:creator>皮娅·安德拉德</dc:creator><dc:creator>刘安迪</dc:creator><dc:creator>伊恩·R·汉弗莱斯</dc:creator><dc:creator>塞尔达·图卡斯兰</dc:creator><dc:creator>凯文·J·卡特勒</dc:creator><dc:creator>马里奥·L·阿列塔-奥尔蒂斯</dc:creator><dc:creator>李亚桥</dc:creator><dc:creator>马修·雷迪</dc:creator><dc:creator>杰弗里·麦克莱恩</dc:creator><dc:creator>钱聪</dc:creator><dc:creator>大卫·贝克</dc:creator><dc:creator>尼廷·S·巴利加</dc:creator><dc:creator>布鲁克彼得森</dc:creator><dc:creator>约瑟夫·D·穆古斯</dc:creator><dc:date>2023-09-08</dc:date><dc:source>细胞</dc:source><dc:title>Patescibacteria 的基因操作为微生物暗物质和表生生活方式提供了机制见解</dc:title><dc:identifier>下午:37683634</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.017</dc:identifier></item><item><title>环氧二十碳三烯酸通过 IFN-I 信号传导预防病毒性心肌炎的心脏功能障碍</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>心肌炎是一种具有挑战性的心脏炎症性疾病，需要更好地了解其发病机制以开发特异性药物疗法。环氧二十碳三烯酸（EET）是由花生四烯酸的 CYP（细胞色素 P450）酶合成的活性分子，并水解为活性较低的二羟基二十碳三烯酸由 sEH（可溶性环氧化物水解酶）产生的 EET 被认为具有抗炎活性。在这里，我们研究了 EET 是否具有免疫调节活性并发挥... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 8 日。doi：10.1161/CIRCRESAHA.123.322619。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心肌炎是一种具有挑战性的心脏炎症性疾病，需要更好地了解其发病机制以开发特异性药物疗法。环氧二十碳三烯酸（EET）是由花生四烯酸的 CYP（细胞色素 P450）酶合成的活性分子，并水解为活性较低的二羟基二十碳三烯酸sEH（可溶性环氧化物水解酶）产生的 EET 被认为具有抗炎活性。在此，我们研究了 EET 是否具有免疫调节活性，并对柯萨奇 B3 病毒引起的心肌炎发挥保护作用。病毒感染心肌炎患者和心肌炎患者中的类二十烷酸环氧化物和二醇水平在小鼠心脏中，与柯萨奇 B3 病毒感染后 sEH 的表达和活性增加相关。使用 sEH 抑制剂可预防柯萨奇 B3 病毒引起的心脏功能障碍和炎症浸润。重要的是，EET/sEH 抑制剂治疗可减弱病毒感染或改善病毒感染通过激活 I 型 IFN（干扰素）信号传导来抵抗耐药性。在分子水平上，EET 增强了 GSK3β（糖原合酶激酶 3 beta）和 TBK1（TANK 结合激酶 1）之间的相互作用，以促进 IFN-β 的产生。我们的研究结果表明， EET 和 sEH 抑制剂可预防柯萨奇 B3 病毒引起的心肌炎的进展，特别是通过增加 IFN 的产生来促进病毒抵抗力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37681352</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322619>10.1161/CIRCRESAHA.123.322619</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681352</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>周周</dc:creator><dc:creator>张敏</dc:creator><dc:creator>赵成成</dc:creator><dc:creator>徐高</dc:creator><dc:creator>郑文</dc:creator><dc:creator>吴俊芳</dc:creator><dc:creator>陈陈</dc:creator><dc:creator>英格丽·弗莱明</dc:creator><dc:creator>胡炯</dc:creator><dc:creator>王道文</dc:creator><dc:date>2023-09-08</dc:date><dc:source>流通研究</dc:source><dc:title>环氧二十碳三烯酸通过 IFN-I 信号传导预防病毒性心肌炎的心脏功能障碍</dc:title><dc:identifier>下午：37681352</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322619</dc:identifier></item><item><title>阿哌沙班剂量与心房颤动和严重慢性肾脏病患者安全性和有效性结果的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>结论：与 2.5 mg 相比，使用 5 mg 阿哌沙班与心房颤动和严重慢性肾脏病患者的出血风险较高相关，但中风/全身性栓塞或死亡风险没有差异，支持阿哌沙班的剂量建议欧洲药品管理局以肾功能为基础，与美国食品和药物管理局发布的不同。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 8 日。doi：10.1161/CIRCULATIONAHA.123.065614。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：美国食品和药物管理局和欧洲药品管理局根据肾功能对房颤患者阿哌沙班剂量的建议不一致。慢性肾病患者的最佳阿哌沙班剂量仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过使用来自 Optum Labs 数据仓库的去识别化电子健康记录数据，确定了 2013 年至 2021 年间开始服用阿哌沙班的心房颤动和慢性肾脏病 4/5 期患者。阿哌沙班剂量（5 与 2.5 mg），通过治疗权重的逆概率调整基线特征。使用细灰色次分布风险模型来解释死亡的竞争风险。使用 Cox 回归来检查阿哌沙班的死亡风险剂量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 4313 名阿哌沙班新使用者中，1705 名（40%）接受 5 mg 治疗，2608 名（60%）接受 2.5 mg。接受 5 mg 阿哌沙班治疗的患者更年轻（平均年龄 72 岁与 80 岁），体重更大（95 岁与 80 岁）。 80 kg）和更高的血清肌酐（2.7 与 2.5 mg/dL）。平均估计肾小球滤过率在各组之间没有差异（24 与 24 mL·min <sup>-1</sup> ·1.73 m <sup>-2</sup> ）。治疗权重分析的逆概率，阿哌沙班 5 mg 与较高的出血风险相关（每 100 人年发生率 4.9 例与 2.9 例事件；发生率差异，每 100 人年 2.0 [95% CI，0.6-3.4] 例事件；次分布风险比，1.63 [95% CI, 1.04-2.54]）。阿哌沙班 5 mg 和 2.5 mg 组之间的卒中/全身性栓塞风险没有差异（每 100 人年分别有 3.3 例和 3.0 例事件；发生率差异为 0.2 [95 %] CI，-1.0 至 1.4] 每 100 人年事件；次分布风险比，1.01 [95% CI，0.59-1.73]），或死亡（每 100 人年 9.9 与 9.4 事件；发生率差异，0.5 [ 95每 100 人年发生事件 % CI，-1.6 至 2.6；风险比，1.03 [95% CI，0.77-1.38]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与 2.5 mg 相比，使用 5 mg 阿哌沙班与心房颤动和严重慢性肾脏病患者的出血风险较高相关，但中风/全身性栓塞或死亡风险没有差异，支持阿哌沙班的剂量建议欧洲药品管理局以肾功能为基础，与美国食品和药物管理局发布的不同。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37681341</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065614>10.1161/CIRCULATIONAHA.123.065614</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681341</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>徐云文</dc:creator><dc:creator>亚历克斯·R·张</dc:creator><dc:creator>莱斯利·英克</dc:creator><dc:creator>玛拉·麦克亚当斯-德马科</dc:creator><dc:creator>摩根·E·格拉姆斯</dc:creator><dc:creator>申正林</dc:creator><dc:date>2023-09-08</dc:date><dc:source>循环</dc:source><dc:title>阿哌沙班剂量与心房颤动和严重慢性肾脏病患者安全性和有效性结果的关系</dc:title><dc:identifier>下午:37681341</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065614</dc:identifier></item><item><title>与参与高级护理改善捆绑付款相关的心血管支出、护理利用和临床结果的变化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>结论：参与 BPCI-A 与模型中提供的心血管医疗事件或手术的支出减少、护理使用的改变或质量提高无关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 8 日。doi：10.1161/CIRCULATIONAHA.123.065109。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：高级护理改善捆绑付款 (BPCI-A) 是一项 Medicare 计划，旨在激励减少从住院开始到出院后 90 天结束的护理支出。心血管疾病是 Medicare 支出的重要驱动因素，是 BPCI-A 关注的领域之一。目前尚不清楚 BPCI-A 是否与模型中 3 种心血管医疗事件或 5 种心血管手术的支出减少或质量提高相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项回顾性队列研究中，我们使用 Medicare 索赔对 2017 年 1 月 1 日至 2019 年 9 月 30 日期间出院的患者进行了双重差分分析，以评估 BPCI-A 医院与匹配的非参与对照医院之间的差异。结果是与对照组相比，实施 BPCI-A 之前和之后 BPCI-A 医院心脏医疗和手术条件的支出差异变化。次要结果包括患者复杂性、护理使用、在家健康天数、再入院、和死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：BPCI-A 医院心脏医疗事件的基线支出为 25 606 美元。BPCI-A 与对照医院心脏医疗事件支出的差异变化为 16 美元（95% CI，-228 美元至 261 美元； <i>P</i> = 0.90）。 BPCI-A 医院心脏手术发作的基线支出为 37 961 美元。心脏手术发作支出的差异变化为 171 美元（95% CI，-429 美元至 772 美元； <i>P</i> = 0.58）。医生护理方面的差异变化很小在 BPCI-A 与对照医院相比，90 天再入院率没有显着差异（差异变化，0.27% [95% CI，-0.25% 至对于医疗事件，差异变化为 0.80%]；对于手术事件，差异变化为 0.31% [95% CI，-0.98% 至 1.60%]）或死亡率（差异变化，对于手术事件，为 -0.14% [95% CI，-0.50% 至 0.23%]医疗事件；差异变化，-0.36% [95% CI，-1.25% 至 0.54%]（对于手术事件）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：参与 BPCI-A 与模型中提供的心血管医疗事件或手术的支出减少、护理使用的改变或质量提高无关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37681315</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065109>10.1161 / CIRCULATIONAHA.123.065109</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681315</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>苏克鲁特·沙希库玛</dc:creator><dc:creator>郑杰</dc:creator><dc:creator>约翰·奥拉夫</dc:creator><dc:creator>阿诺德·M·爱泼斯坦</dc:creator><dc:creator>凯伦·E·乔恩特·马多克斯</dc:creator><dc:date>2023-09-08</dc:date><dc:source>循环</dc:source><dc:title>与参与高级护理改善捆绑付款相关的心血管支出、护理利用和临床结果的变化</dc:title><dc:identifier>下午:37681315</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065109</dc:identifier></item><item><title>细胞外周分离是心脏传导的主要决定因素</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681314/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>结论：心脏传导与细胞外阻力无关，但与周围分离呈双相相关，这提供了证据表明，在正常间隙连接耦合条件下，CV 和细胞外容量之间的关系是由触觉机制决定的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 8 日。doi：10.1161/CIRCRESAHA.123.322567。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心脏传导被认为是通过间隙连接发生的。最近的证据支持心电耦合是心脏电通讯的另一种机制。通过间隙连接的传导预测传导速度 (CV) 和大量细胞外电阻之间的直接关系。相比之下，心电耦合该理论的前提是 CV 与闰盘（如会周）内特殊细胞外裂隙的体积之间存在双相关系。我们的目标是确定心室 CV 与微米级和纳米级细胞外空间结构变化之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对灌注有渗透剂白蛋白、甘露醇、葡聚糖 70 kDa 或葡聚糖 2 MDa 的光学绘图豚鼠全心制剂的传导和 Cx43 (connexin43) 蛋白表达进行定量。对离体豚鼠心室肌​​细胞中的峰值钠电流进行定量通过阻抗谱量化细胞外电阻。在光漂白后荧光恢复的异源表达系统中评估细胞间通讯。通过透射电子显微照片量化会周宽度。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：甘露醇显着降低传播横向上的 CV，而白蛋白和两种葡聚糖则增加。白蛋白和 70 kDa 葡聚糖的组合相对于单独的白蛋白降低了 CV。甘露醇降低了细胞外阻力，但白蛋白没有改变，并且两种葡聚糖均增加。渗透剂未显着改变 Cx43 表达、电导和峰值钠电流。根据渗透剂，周周宽度按从最窄到最宽的顺序依次是白蛋白和葡聚糖，70 kDa；白蛋白或葡聚糖，70 kDa； 2 MDa；右旋糖酐，70 kDa 或无渗透剂，和甘露醇。以相同顺序比较时，CV 与周膜宽度呈双相相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：心脏传导与细胞外阻力无关，但与周围分离呈双相相关，这提供了证据表明，在正常间隙连接耦合条件下，CV 和细胞外容量之间的关系是由触觉机制决定的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681314/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37681314</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322567>10.1161/CIRCRESAHA.123.322567</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681314</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>威廉·P·亚当斯</dc:creator><dc:creator>特里斯坦·B·赖希</dc:creator><dc:creator>赵亚军</dc:creator><dc:creator>拉斐尔·达瓦洛斯</dc:creator><dc:creator>莎拉·巴雷特</dc:creator><dc:creator>D瑞安·金</dc:creator><dc:creator>钱德拉·B·贝恩</dc:creator><dc:creator>卡特里娜·科鲁奇-张</dc:creator><dc:creator>格蕾丝·布莱尔</dc:creator><dc:creator>亚历山德拉·汉伦</dc:creator><dc:creator>艾丽西娅·洛萨诺</dc:creator><dc:creator>伦加萨伊·维拉拉哈万</dc:creator><dc:creator>万小平</dc:creator><dc:creator>伊莎贝尔·德谢尼</dc:creator><dc:creator>詹姆斯·W·史密斯</dc:creator><dc:creator>格雷戈里·S·霍克</dc:creator><dc:creator>罗伯特·G·古迪</dc:creator><dc:creator>史蒂文·波尔津</dc:creator><dc:date>2023-09-08</dc:date><dc:source>流通研究</dc:source><dc:title>细胞外周分离是心脏传导的主要决定因素</dc:title><dc:identifier>下午：37681314</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322567</dc:identifier></item><item><title>保留射血分数的临床和实验性心力衰竭中的克隆造血</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230912180730&amp;v=2.17.9.post6+86293ac<description>结论：CH 与 HFpEF 患者较差的心功能和预后相关，Tet2 介导的 CH 小鼠实验模型显示出更多的 HFpEF 特征。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.064170. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Clonal hematopoiesis (CH), which results from an array of nonmalignant driver gene mutations, can lead to altered immune cell function and chronic disease, and has been associated with worse outcomes in patients with heart failure (HF) with reduced ejection fraction. However, the role of CH in the prognosis of HF with preserved ejection fraction (HFpEF) has been understudied. This study aimed to characterize CH in patients with HFpEF and elucidate its causal role in a murine model. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Using a panel of 20 candidate CH driver genes and a variant allele frequency cutoff of 0.5%, ultradeep error-corrected sequencing identified CH in a cohort of 81 patients with HFpEF (mean age, 71±6 years; ejection fraction, 63±5%) and 36 controls without a diagnosis of HFpEF (mean age, 74±7 years; ejection fraction, 61.5±8%). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Compared with controls, there was an enrichment of <i>TET2</i> -mediated CH in the HFpEF patient cohort (12% versus 0%, respectively; <i>P</i> =0.02). In the HFpEF cohort, patients with CH exhibited exacerbated diastolic dysfunction in terms of E/e&#39; (14.9 versus 11.7, respectively; <i>P</i> =0.0096) and E/A (1.69 versus 0.89, respectively; <i>P</i> =0.0206) compared with those without CH. The association of CH with exacerbated diastolic dysfunction was corroborated in a validation cohort of 59 individuals with HFpEF. In accordance, patients with HFpEF with CH and age ≥70 years exhibited worse prognosis in terms of 5-year cardiovascular-related hospitalization rate (hazard ratio, 5.06; <i>P</i> =0.042) compared with patients with HFpEF without CH and age ≥70 years. To investigate the causal role of CH in HFpEF, nonconditioned mice underwent adoptive transfer with <i>Tet2</i> -wild-type or <i>Tet2</i> -deficient bone marrow and were subsequently subjected to a high-fat diet/L-NAME (N <sub>ω</sub> -nitro-l-arginine methyl ester) combination treatment to induce features of HFpEF. This model of <i>Tet2</i> -CH exacerbated cardiac hypertrophy by heart weight/tibia length and cardiomyocyte size, diastolic dysfunction by E/e&#39; and left ventricular end-diastolic pressure, and cardiac fibrosis compared with the <i>Tet2</i> -wild-type condition. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of <i>Tet2</i> -mediated CH displays greater features of HFpEF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37681311</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064170>10.1161/CIRCULATIONAHA.123.064170</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681311</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Jesse Cochran</dc:creator><dc:creator> Yoshimitsu Yura</dc:creator><dc:creator> Mark C Thel</dc:creator><dc:creator> Heather Doviak</dc:creator><dc:creator> Ariel H Polizio</dc:creator><dc:creator> Yuka Arai</dc:creator><dc:creator> Yohei Arai</dc:creator><dc:creator> Keita Horitani</dc:creator><dc:creator> Eunbee Park</dc:creator><dc:creator> Nicholas W Chavkin</dc:creator><dc:creator> Anupreet Kour</dc:creator><dc:creator> Soichi Sano</dc:creator><dc:creator> Nitin Mahajan</dc:creator><dc:creator> Megan Evans</dc:creator><dc:creator> Mahalia Huba</dc:creator><dc:creator> Nadia Martinez Naya</dc:creator><dc:creator> Hanna Sun</dc:creator><dc:creator> Youngho Ban</dc:creator><dc:creator> Karen K Hirschi</dc:creator><dc:creator> Stefano Toldo</dc:creator><dc:creator> Antonio Abbate</dc:creator><dc:creator> Todd E Druley</dc:creator><dc:creator> Frederick L Ruberg</dc:creator><dc:creator> Mathew S Maurer</dc:creator><dc:creator> Justin A Ezekowitz</dc:creator><dc:creator> Jason RB Dyck</dc:creator><dc:creator> Kenneth Walsh</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation</dc:source><dc:title> Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction</dc:title><dc:identifier> pmid:37681311</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064170</dc:identifier></item><item><title> Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37681309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912180730&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Taken together, our results suggest how epigenetic dysregulation of glycolysis pathway enhancers could potentially be targeted to treat heart failure in the elderly. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Sep 8. doi: 10.1161/CIRCRESAHA.123.322676. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RATIONALE: Heart failure is typical in the elderly. Metabolic remodeling of cardiomyocytes underlies inexorable deterioration of cardiac function with aging: glycolysis increases at the expense of oxidative phosphorylation, causing an energy deficit contributing to impaired contractility. Better understanding of the mechanisms of this metabolic switching could be critical for reversing the condition. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To investigate the role of 3 histone modifications (H3K27ac, H3K27me3, and H3K4me1) in the metabolic remodeling occurring in the aging heart. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We report a set of species-conserved enhancers associated with transcriptional changes underlying age-related metabolic remodeling in cardiomyocytes. Activation of the enhancer region of <i>Hk2</i> -a key glycolysis pathway gene-was fostered in old age-onset mouse heart by pseudohypoxia, wherein hypoxia-related genes are expressed under normal O <sub>2</sub> levels, via increased activity of the transcriptional coactivator p300 (E1A-associated binding protein p300)/CBP (CREB-binding protein). Pharmacological inhibition of p300/CBP before the onset of cardiac aging led to a more aerobic, less glycolytic, metabolic state, improved heart contractility, and overall blunting of cardiac decline. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Taken together, our results suggest how epigenetic dysregulation of glycolysis pathway enhancers could potentially be targeted to treat heart failure in the elderly.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37681309</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322676>10.1161/CIRCRESAHA.123.322676</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681309</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Simone Serio</dc:creator><dc:creator> Christina Pagiatakis</dc:creator><dc:creator> Elettra Musolino</dc:creator><dc:creator> Arianna Felicetta</dc:creator><dc:creator> Pierluigi Carullo</dc:creator><dc:creator> Javier Laura Frances</dc:creator><dc:creator> Laura Papa</dc:creator><dc:creator> Giacomo Rozzi</dc:creator><dc:creator> Nicolò Salvarani</dc:creator><dc:creator> Michele Miragoli</dc:creator><dc:creator> Rosalba Gornati</dc:creator><dc:creator> Giovanni Bernardini</dc:creator><dc:creator> Gianluigi Condorelli</dc:creator><dc:creator> Roberto Papait</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation research</dc:source><dc:title> Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis</dc:title><dc:identifier> pmid:37681309</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322676</dc:identifier></item><item><title> An apple in the heart: a rare case of cardiac hyper-immunoglobulin E syndrome</title><link/> https://pubmed.ncbi.nlm.nih.gov/37680109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912180730&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 8:ehad565. doi: 10.1093/eurheartj/ehad565. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37680109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37680109</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad565>10.1093/eurheartj/ehad565</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37680109</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Jie Yin</dc:creator><dc:creator> Xiao-Hang Liu</dc:creator><dc:creator> Wei Chen</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> European heart journal</dc:source><dc:title> An apple in the heart: a rare case of cardiac hyper-immunoglobulin E syndrome</dc:title><dc:identifier> pmid:37680109</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad565</dc:identifier></item><item><title> Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges</title><link/> https://pubmed.ncbi.nlm.nih.gov/37680108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912180730&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 8:ehad593. doi: 10.1093/eurheartj/ehad593. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37680108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37680108</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad593>10.1093/eurheartj/ehad593</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37680108</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Giovanna Liuzzo</dc:creator><dc:creator> Massimo Volpe</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> European heart journal</dc:source><dc:title> Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges</dc:title><dc:identifier> pmid:37680108</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad593</dc:identifier></item><item><title> Menopause-Biology, consequences, supportive care, and therapeutic options</title><link/> https://pubmed.ncbi.nlm.nih.gov/37678251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912180730&amp;v=2.17.9.post6+86293ac<description> Menopause is the cessation of ovarian function, with loss of reproductive hormone production and irreversible loss of fertility. It is a natural part of reproductive aging. The physiology of the menopause is complex and incompletely understood. Globally, menopause occurs around the age of 49 years, with geographic and ethnic variation. The hormonal changes of the menopause transition may result in both symptoms and long-term systemic effects, predominantly adverse effects on cardiometabolic and... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 5:S0092-8674(23)00905-4. doi: 10.1016/j.cell.2023.08.016. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Menopause is the cessation of ovarian function, with loss of reproductive hormone production and irreversible loss of fertility. It is a natural part of reproductive aging. The physiology of the menopause is complex and incompletely understood. Globally, menopause occurs around the age of 49 years, with geographic and ethnic variation. The hormonal changes of the menopause transition may result in both symptoms and long-term systemic effects, predominantly adverse effects on cardiometabolic and musculoskeletal health. The most effective treatment for bothersome menopausal symptoms is evidence-based, menopausal hormone therapy (MHT), which reduces bone loss and may have cardiometabolic benefits. Evidence-based non-hormonal interventions are also available for symptom relief. Treatment should be individualized with shared decision-making. Most MHT regimens are not regulator approved for perimenopausal women. Studies that include perimenopausal women are needed to determine the efficacy and safety of treatment options. Further research is crucial to improve menopause care, along with research to guide policy and clinical practice.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37678251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37678251</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.016>10.1016/j.cell.2023.08.016</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37678251</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Susan R Davis</dc:creator><dc:creator> JoAnn Pinkerton</dc:creator><dc:creator> Nanette Santoro</dc:creator><dc:creator> Tommaso Simoncini</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> Cell</dc:source><dc:title> Menopause-Biology, consequences, supportive care, and therapeutic options</dc:title><dc:identifier> pmid:37678251</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.016</dc:identifier></item><item><title> Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events</title><link/> https://pubmed.ncbi.nlm.nih.gov/37676198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912180730&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: As few as about 2,600 and about 2,800 steps/d yield significant mortality and CVD benefits, with progressive risk reductions up to about 8,800 and about 7,200 steps/d, respectively. Additional mortality benefits were found at a moderate to high vs a low step cadence. These findings can extend contemporary physical activity prescriptions given the easy-to-understand concept of step count. (Dose-Response Relationship Between Daily Step Count and Health Outcomes: A Systematic Review... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 26:S0735-1097(23)06400-8. doi: 10.1016/j.jacc.2023.07.029. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The minimal and optimal daily step counts for health improvements remain unclear. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: A meta-analysis was performed to quantify dose-response associations of objectively measured step count metrics in the general population. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Electronic databases were searched from inception to October 2022. Primary outcomes included all-cause mortality and incident cardiovascular disease (CVD). Study results were analyzed using generalized least squares and random-effects models. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In total, 111,309 individuals from 12 studies were included. Significant risk reductions were observed at 2,517 steps/d for all-cause mortality (adjusted HR [aHR]: 0.92; 95% CI: 0.84-0.999) and 2,735 steps/d for incident CVD (aHR: 0.89; 95% CI: 0.79-0.999) compared with 2,000 steps/d (reference). Additional steps resulted in nonlinear risk reductions of all-cause mortality and incident CVD with an optimal dose at 8,763 (aHR: 0.40; 95% CI: 0.38-0.43) and 7,126 steps/d (aHR: 0.49; 95% CI: 0.45-0.55), respectively. Increments from a low to an intermediate or a high cadence were independently associated with risk reductions of all-cause mortality. Sex did not influence the dose-response associations, but after stratification for assessment device and wear location, pronounced risk reductions were observed for hip-worn accelerometers compared with pedometers and wrist-worn accelerometers. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: As few as about 2,600 and about 2,800 steps/d yield significant mortality and CVD benefits, with progressive risk reductions up to about 8,800 and about 7,200 steps/d, respectively. Additional mortality benefits were found at a moderate to high vs a low step cadence. These findings can extend contemporary physical activity prescriptions given the easy-to-understand concept of step count. (Dose-Response Relationship Between Daily Step Count and Health Outcomes: A Systematic Review and Meta-Analyses; CRD42021244747).</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37676198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912180730&v=2.17.9.post6+86293ac">37676198</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.029>10.1016/j.jacc.2023.07.029</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37676198</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Niels A Stens</dc:creator><dc:creator> Esmée A Bakker</dc:creator><dc:creator> Asier Mañas</dc:creator><dc:creator> Laurien M Buffart</dc:creator><dc:creator> Francisco B Ortega</dc:creator><dc:creator> Duck-Chul Lee</dc:creator><dc:creator> Paul D Thompson</dc:creator><dc:creator> Dick HJ Thijssen</dc:creator><dc:creator> Thijs MH Eijsvogels</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events</dc:title><dc:identifier> pmid:37676198</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.029</dc:identifier></item></channel></rss>